{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:42:35Z","timestamp":1768750955591,"version":"3.49.0"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction Pharmacotherapy with drugs like naltrexone or acamprosate is\n                    a well-evaluated element in the treatment of alcohol dependence (AD). However,\n                    in many countries, these medications are rarely administered. The objective of\n                    the present study was to identify from patients\u2019 perspective factors\n                    that prevent the initiation and compliance with pharmacological treatment of\n                    AD.<\/jats:p><jats:p>\n          Methods Patients from inpatient alcohol withdrawal treatment underwent a\n                    standardized interview. Questions included socio-demographic data, history of\n                    AD, treatment history, knowledge and personal experience regarding\n                    pharmacotherapy of AD, and personal views about the causes of AD.<\/jats:p><jats:p>\n          Results Three hundred patients (mean age 47.3 years, 27.7% female,\n                    mean duration of AD 8.9 years, 67% with a history of previous inpatient\n                    withdrawal treatment) were included. The majority of patients (58.7%)\n                    already knew drugs for the pharmacotherapy of AD. Thirty percent had ever used\n                    such medications, most often acamprosate. Except for disulfiram, pharmacotherapy\n                    of AD had lasted only a few weeks, on average. Medication usually had been\n                    applied without additional psychotherapy. No severe side effects were reported.\n                    Patients had often stopped pharmacotherapy on their own, when assuming they had\n                    reached stable abstinence. Openness to start pharmacotherapy for AD was\n                    currently stated by 67% of the total sample. In multiple logistic\n                    regression, openness was predicted by having a concept of AD as a medical\n                    disease and by a shorter duration of AD.<\/jats:p><jats:p>\n          Discussion To improve the administration of pharmacotherapy for AD\n                    implementation strategies should be systematically developed and evaluated with\n                    a focus on the concept of AD as a medical disease.<\/jats:p>","DOI":"10.1055\/a-2190-4842","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:07:15Z","timestamp":1701821235000},"page":"21-29","source":"Crossref","is-referenced-by-count":4,"title":["Patient Perspectives on Pharmacotherapy of Alcohol\n                    Dependence"],"prefix":"10.1055","volume":"57","clinical-trial-number":[{"clinical-trial-number":"drks00013881","registry":"10.18810\/drks"}],"author":[{"given":"Julian","family":"Wellensiek","sequence":"additional","affiliation":[{"name":"LVR Hospital Bonn, Department of Addiction Disorders and Psychotherapy,\n                    Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Specka","sequence":"additional","affiliation":[{"name":"LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty\n                    of Medicine, University of Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Just","sequence":"additional","affiliation":[{"name":"Witten\/Herdecke University, Faculty of Health, Department of\n                    Medicine, Witten, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Banger","sequence":"additional","affiliation":[{"name":"LVR Hospital Bonn, Department of Addiction Disorders and Psychotherapy,\n                    Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Bonnet","sequence":"additional","affiliation":[{"name":"LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty\n                    of Medicine, University of Duisburg-Essen, Essen, Germany"},{"name":"Department of Psychiatry, Psychotherapy and Psychosomatic Medicine,\n                    Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the\n                    University of Duisburg\/Essen, Castrop-Rauxel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[{"name":"LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty\n                    of Medicine, University of Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol use disorders","volume":"394","author":"A F Carvalho","year":"2019","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/15622975.2016.1246752","article-title":"Guidelines for biological treatment of substance use and related disorders, part\n                    1: Alcoholism, first revision","volume":"18","author":"M Soyka","year":"2017","journal-title":"World J Biol Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: A review","volume":"320","author":"H R Kranzler","year":"2018","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A\n                    systematic review and meta-analysis","volume":"311","author":"D E Jonas","year":"2014","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/YCO.0000000000000512","article-title":"Selecting an appropriate alcohol pharmacotherapy: Review of recent findings","volume":"32","author":"S Castr\u00e9n","year":"2019","journal-title":"Curr Opin Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/add.15384","article-title":"Real-world effectiveness of pharmacological treatments of alcohol use disorders\n                    in a Swedish nation-wide cohort of 125 556 patients","volume":"116","author":"M Heikkinen","year":"2021","journal-title":"Addiction"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1530-0277.2006.00013.x","article-title":"Follow-up of 180 alcoholic patients for up to 7 years after outpatient\n                    treatment: impact of alcohol deterrents on outcome","volume":"30","author":"H Krampe","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US: Results from the 2019\n                    National Survey on Drug Use and Health (Letter)","volume":"78","author":"B Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.mayocp.2020.01.030","article-title":"Evidence-based pharmacotherapies for alcohol use disorder: Clinical pearls","volume":"95","author":"J Fairbanks","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/a-0896-2757","article-title":"Very low frequency of drug therapy of alcohol dependence in Germany - Analysis\n                    of data of a statutory health insurance","volume":"53","author":"N Scherbaum","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"108964","DOI":"10.1016\/j.drugalcdep.2021.108964","article-title":"Pharmacotherapy for alcohol use disorders - Unequal provision across\n                    sociodemographic factors and co-morbid conditions. A cohort study of the total\n                    population in Sweden","volume":"227","author":"S Wallhed Finn","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212308","article-title":"Practical outpatient pharmacotherapy for alcohol use disorder","volume":"7","author":"Y Kim","year":"2018","journal-title":"Drugs Context"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S2215-0366(19)30213-5","article-title":"Prevention, screening and treatment for heavy drinking and alcohol use\n                    disorder","volume":"6","author":"J Knox","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1097\/ADM.0000000000000918","article-title":"First-line medications for the outpatient treatment of alcohol use disorder: A\n                    systematic review of perceived barriers","volume":"16","author":"C Gregory","year":"2022","journal-title":"J Addict Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1360-0443.2003.00377.x","article-title":"Physicians\u2019 opinions about medications to treat alcoholism","volume":"98","author":"T L Mark","year":"2003","journal-title":"Addiction"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1521-0391.2003.tb00543.x","article-title":"Barriers to the use of medications to treat alcoholism","volume":"12","author":"T L Mark","year":"2003","journal-title":"Am J Addict"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"916","DOI":"10.15288\/jsa.2000.61.916","article-title":"Reliability and validity of the German version of the European Addiction\n                    Severity Index (EuropASI)","volume":"61","author":"A Scheurich","year":"2000","journal-title":"J Stud Alcohol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3109\/10826088709027474","article-title":"Public attitudes to the disease concept of alcoholism","volume":"22","author":"J Crawford","year":"1987","journal-title":"Int J Addict"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/s0895-4356(96)00236-3.","article-title":"A simulation study of the number of events per variable in\n                    logistic regression analysis","volume":"49","author":"P Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"ref21","first-page":"250","article-title":"Therapieerfolg Alkoholabh\u00e4ngiger nach qualifizierter entzugsbehandlung\n                    und konventioneller Entgiftung [Success of alcohol dependents after\n                    comprehensive withdrawal treatment or conventional detoxification\n                    treatment]","volume":"46","author":"U Bauer","year":"2000","journal-title":"SUCHT"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"10817410","DOI":"10.1016\/j.drugalcdep.2020.108174","article-title":"Correlates of alcohol use disorder pharmacotherapy receipt in medically insured\n                    patients","volume":"214","author":"A Rittenberg","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/papt.12247","article-title":"Causal explanations of depression and treatment credibility in adults with\n                    untreated depression: Examining attribution theory","volume":"93","author":"M Zimmermann","year":"2020","journal-title":"Psychol Psychother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13011-015-0028-z","article-title":"Alcohol use disorder severity and reported reasons not to seek treatment: A\n                    cross-sectional study in European primary care practices","volume":"10","author":"C Probst","year":"2015","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12875-015-0308-8","article-title":"Alcohol dependence and treatment utilization in Europe - A representative\n                    cross-sectional study in primary care","volume":"16","author":"J Rehm","year":"2015","journal-title":"BMC Fam Pract"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00127-002-0576-1","article-title":"Who seeks treatment for alcohol dependence? Findings from the Australian\n                    National Survey of mental health and wellbeing","volume":"37","author":"Australian National Survey of Mental H,\n                            Wellbeing","year":"2002","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12875-020-01288-6","article-title":"Evidence based models of care for the treatment of alcohol use disorder in\n                    primary health care settings: A systematic review","volume":"21","author":"S A Rombouts","year":"2020","journal-title":"BMC Fam Pract"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","article-title":"Barriers to use of pharmacotherapy for addiction disorders and how to overcome\n                    them","volume":"13","author":"E M Oliva","year":"2011","journal-title":"Curr Psychiatry Rep"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1521-0391.2003.tb00543.x","article-title":"Barriers to the use of medications to treat alcoholism","volume":"12","author":"T L Mark","year":"2003","journal-title":"Am J Addict"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/08897077.2019.1576089","article-title":"Patient perspectives on alcohol use disorder pharmacotherapy and integration of\n                    treatment into primary care settings","volume":"40","author":"S J Haley","year":"2019","journal-title":"Subst Abus"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0042-122225","article-title":"Die behandlung des alkoholentzugs mit oxazepam oder clomethiazol \u2013 eine\n                    naturalistische beobachtungsstudie [Treatment of alcohol withdrawal syndrome\n                    with oxazepam or clomethiazole - A naturalistic observational study]","volume":"45","author":"U Verthein","year":"2018","journal-title":"Psychiatr Prax"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/jclp.23316","article-title":"Association of impulsivity with quality of life and well-being after alcohol\n                    withdrawal treatment","volume":"78","author":"D Reichl","year":"2022","journal-title":"J Clin Psychol"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2190-4842.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:31:05Z","timestamp":1730817065000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2190-4842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":31,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,9]]},"published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2190-4842","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}